Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Susan Carson

Nurse Practitioner, Pediatrics Los Angeles, CA Nurse Practitioner

NPI 1386810810 CMS profile 1086019

4650 W Sunset Blvd, Ms #54, Los Angeles, CA 90027

Open in the dashboard

General payments

$85,078

170 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Susan Carson of Los Angeles, CA is reported in the CMS Open Payments database as having received $85,078 across 170 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $29,577 51
2024 General $17,678 40
2023 General $15,498 34
2022 General $13,935 29
2021 General $8,390 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susan Carson
  • Nurse Practitioner, Pediatrics median
  • Middle half of Nurse Practitioner, Pediatrics
  • National median

In program year 2025, general payments to Susan Carson were reported at $29,577. Among 7,458 Nurse Practitioner, Pediatrics profiles paid that year, the median was $93 and the middle half received between $35 and $201.

Show as a table
Year Susan Carson Nurse Practitioner, Pediatrics median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $8,390 $60 $23–$142 $132
2022 $13,935 $72 $27–$161 $149
2023 $15,498 $89 $35–$185 $160
2024 $17,678 $93 $34–$199 $164
2025 $29,577 $93 $35–$201 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Agios Pharmaceuticals, Inc. $35,090 62 payments
  2. Pfizer Inc. $24,892 50 payments
  3. Chiesi USA, Inc. $10,411 21 payments
  4. Global Blood Therapeutics, Inc. $8,499 27 payments
  5. Celgene Corporation $2,832 2 payments
  6. E.R. Squibb & Sons, L.L.C. $2,049 2 payments
  7. Novartis Pharmaceuticals Corporation $1,028 1 payment
  8. Novo Nordisk Inc $141 2 payments
  9. bluebird bio, Inc. $136 3 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $31,438 27 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24,044 28 payments
  3. Travel and Lodging $15,945 54 payments
  4. Honoraria $9,000 16 payments
  5. Food and Beverage $3,447 43 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $1,203 2 payments
Products named General payments · program years 2021–2025
  1. PYRUKYND $35,090 62 payments
  2. OXBRYTA Hematology $21,745 43 payments
  3. FERRIPROX Hematology, Disease $7,618 12 payments
  4. OXBRYTA Sickle Cell Disease $6,233 22 payments
  5. REBLOZYL $3,699 3 payments
  6. FERRIPROX Treat Iron Overload From Thalassemia, Sickle Cell Or Another Anemia $2,224 7 payments
  7. ADAKVEO $1,028 1 payment
  8. Zynteglo $120 2 payments
  9. LYFGENIA $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

22

Median for Nurse Practitioner: 389

Drug cost

$37,353

Median for Nurse Practitioner: $21,885

Branded share of claims

0%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Deferasirox Generic 22 $37,353

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PYRUKYND
  • Agios Pharmaceuticals, Inc. $7,086
$7,086 — —
OXBRYTA
  • PFIZER INC. $6,777
$6,777 — —
FERRIPROX
  • CHIESI USA, INC. $298
$298 — —
LYFGENIA
  • bluebird bio, Inc. $17
$17 — —
Zynteglo
  • bluebird bio, Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

170 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Pediatrics in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record